Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.84 |
| ▸ | MMP13 | P45452 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.77 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 4/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334358 | 0.92 | MEN1 (0.90) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL5335238 | 0.91 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL5335082 | 0.89 | MEN1 (0.90) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL108263 | 0.88 | ALDH1A1 (0.92) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL6781831 | 0.87 | HSP90AA1 (0.82) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL3722808 | 0.87 | MEN1 (0.85) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL12700347 | 0.86 | HPGD (0.72) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL11717444 | 0.86 | NPC1 (0.76) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL2958885 | 0.86 | HSP90AA1 (0.76) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL647939 | 0.86 | RAB9A (0.84) | MEN1KMT2ALMNAMAPK1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | DEVGEN NV (BE) | 2008-02-14 | — | — | US | claimed |
| EP-1838690-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | Devgen N.V. (BE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006066879-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | DEVGEN N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | claimed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | claimed |
| EP-2258356-B1 | CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES | CT INGENIERIA GENETICA BIOTECNOLOGIA (CU) | 2017-09-27 | — | — | EP | disclosed |
| US-8530506-B2 | Process for production of biphenyl derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530506-B2 | Process for production of biphenyl derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530506-B2 | Process for production of biphenyl derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20130109714-A1 | NEURODEGENERATIVE DISEASE THERAPEUTIC AGENT | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130109714-A1 | NEURODEGENERATIVE DISEASE THERAPEUTIC AGENT | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-05-02 | — | — | US | disclosed |
| CN-102712606-A | Process for production of biphenyl derivative | MITSUBISHI TANABE PHARMA CORP | 2012-10-03 | — | — | CN | disclosed |
| EP-2502919-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20120232283-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232283-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | DEVGEN NV (BE) | 2008-02-14 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| CN-1118595-A | Anthranilic acid derivative | EISAI CO LTD (JP) | 1996-03-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | KCNA4, HCN4, KCNN4 | MEN1 2435/4885KMT2A 1394/4885LMNA 904/4885 |
| US-20130109714-A1 | NEURODEGENERATIVE DISEASE THERAPEUTIC AGENT | SNCA, NLN, GAP43 | MEN1 4500/4885KMT2A 3716/4885LMNA 2931/4885 |
| US-20120232283-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | AGTR2, AGTR1, ACE | MEN1 4281/4885KMT2A 1260/4885LMNA 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.